Financial Performance - The Group's revenue for the Relevant Period was $6.8 million, a decrease of $0.2 million or 3.3% compared to $7.1 million in the Previous Period[14]. - The Group's profit for the Relevant Period was $173,000, down from a profit of $506,000 in the Previous Period[14]. - Gross profit for the Relevant Period was $2.3 million, compared to $2.5 million in the Previous Period[16]. - The Group's earnings per share for the Relevant Period were 0.02 cents, down from 0.06 cents in the Previous Period[16]. - The total comprehensive income for the period ended March 31, 2025, was $173,000, an increase from $506,000 for the period ended March 31, 2024[18]. - Consolidated profit before taxation for 2025H1 was $267,000, a decline of 55.3% compared to $596,000 in 2024H1[38]. - Segment profit for 2025H1 was $2,304,000, down 11.4% from $2,494,000 in 2024H1[38]. - Total revenue for 2025H1 was $6,837,000, a decrease of 3.25% from $7,067,000 in 2024H1[35]. Expenses and Liabilities - Selling and distribution expenses increased to $1.046 million from $0.914 million in the Previous Period[16]. - Employee costs, including Directors' remuneration, increased to $1.6 million during the Relevant Period, up from $1.3 million in the previous period[100]. - The Group's current taxation for 2025H1 was $94,000, compared to $90,000 in 2024H1[41]. - The Group's total liabilities were $3.3 million as of March 31, 2025, down from $3.6 million as of September 30, 2024[86]. Assets and Equity - Total assets as of March 31, 2025, were $21.695 million, slightly down from $21.785 million as of September 30, 2024[17]. - Total equity attributable to shareholders increased to $18.364 million from $18.191 million[17]. - The total equity of the company increased to $18,364,000 as of March 31, 2025, compared to $17,334,000 as of March 31, 2024, indicating a growth of 5.9%[18]. - Cash and cash equivalents rose to $3.682 million from $3.453 million[17]. - Cash and bank balances at the end of the first half of 2025 were $3,682,000, up from $2,868,000 at the end of the first half of 2024, representing a 28.4% increase[19]. Dividends - The Board has resolved not to declare any dividend for the Relevant Period[14]. - The company has resolved not to declare any dividend for 2025H1, consistent with 2024H1[81]. Business Operations - The Group's principal activity remains the supply of tissue products to corporate customers in Singapore, with a focus on tissue and hygiene-related products[22][28]. - The company remains optimistic about industry growth in Singapore, emphasizing the necessity of tissue products[63][64]. - Major customer Company A contributed $1,142,000 to revenue in 2025H1, down from $1,295,000 in 2024H1[38]. - Sales of hygiene-related products decreased by 14.3%, amounting to a reduction of $64,000[80]. Corporate Governance - The company has adopted and complied with the Corporate Governance Code, with a noted deviation regarding the roles of Chairman and CEO being held by the same individual[135]. - The Audit Committee consists of three independent non-executive Directors, ensuring proper oversight of financial statements[136]. - All Directors confirmed compliance with the Required Standard of Dealings during the Relevant Period[125]. Future Outlook - Future outlook indicates a revenue growth target of 15% for FY2025, driven by new product launches and market expansion strategies[147]. - The company is investing in research and development for innovative technologies, with a budget allocation of HK$50 million for FY2024[148]. - Market expansion plans include entering two new international markets by the end of FY2025, aiming for a 10% market share in each[145]. - A new product line is set to launch in Q1 FY2025, expected to contribute an additional HK$20 million in revenue[147]. - The company aims to improve operational efficiency by 5% through process optimization initiatives in FY2024[148]. Shareholder Information - Mr. Chua Liang Sie holds 552,000,000 shares, representing 69% of the total issued shares of YJH Group Limited[112]. - Mr. Chua Liang Chui holds 552,000,000 shares, also representing 69% of the total issued shares of YJH Group Limited[112]. - YJH Group Limited is approximately 82.76% owned by Mr. Chua Liang Sie and 17.24% by Mr. Chua Liang Chui[113]. Compliance and Regulations - The company has confirmed compliance with the trading standards by all Directors during the relevant period[131]. - The company is committed to ensuring that its business activities and decision-making processes are regulated in a prudent manner[134]. - Forward-looking statements in the report involve known and unknown risks that could cause actual results to differ materially[139].

Financial Performance - The Group's revenue for the Relevant Period was $6.8 million, representing a slight decrease of $0.2 million or 3.3% compared to $7.1 million in the Previous Period[18]. - The Group's profit for the Relevant Period was $173,000, down from a profit of $506,000 in the Previous Period[19]. - Gross profit for the Relevant Period was $2.3 million, compared to $2.5 million in the Previous Period[20]. - Profit before taxation was $267,000, down from $596,000 in the Previous Period[20]. - Earnings per share for the Relevant Period were 0.02 cents, compared to 0.06 cents in the Previous Period[20]. - Total revenue for 2025H1 was $6,837,000, a decrease of 3.25% from $7,067,000 in 2024H1[39]. - Segment profit for tissue products was $2,048,000, down 5.52% from $2,168,000 in 2024H1[39]. - Revenue from external customers for hygiene-related products was $382,000, a decline of 14.36% from $446,000 in 2024H1[39]. - The Group's consolidated profit before taxation for 2025H1 was $267,000, a decrease of 55.32% compared to $596,000 in 2024H1[42]. - Basic earnings per share for 2025H1 was 0.02 cents, down from 0.06 cents in 2024H1[48]. - Net profit attributable to shareholders for the period was $173,000, down from $506,000 in the same period last year[83]. - Sales of hygiene-related products decreased by $64,000, representing a decrease of 14.3%[84]. Expenses and Costs - Selling and distribution expenses increased to $1.046 million from $0.914 million in the Previous Period[20]. - Administrative expenses remained relatively stable at $1.033 million compared to $1.021 million in the Previous Period[20]. - The Group's cost of sales for the Relevant Period was $4.5 million, slightly down from $4.6 million in the Previous Period[20]. - Total unallocated expenses increased to $2,079,000 in 2025H1 from $1,935,000 in 2024H1[42]. - The cost of inventories for 2025H1 was $3,905,000, a decrease from $4,152,000 in 2024H1[43]. - Selling and distribution expenses increased from $0.9 million to $1.0 million, an increase of 14.4% due to inflation and changes in the sales commission structure[75]. Assets and Liabilities - Total assets decreased slightly to $21,695,000 as of March 31, 2025, from $21,785,000 on September 30, 2024, representing a decline of approximately 0.4%[21]. - Total liabilities decreased to $3,331,000 as of March 31, 2025, down from $3,594,000, representing a reduction of about 7.3%[21]. - Trade and other receivables increased to $2,381,000 as of March 31, 2025, up from $2,273,000, indicating a rise of about 4.8%[21]. - Trade receivables as of March 31, 2025, were $2,187,000, slightly up from $2,183,000 as of September 30, 2024[52]. - Trade payables as of March 31, 2025, were $457,000, down from $546,000 as of September 30, 2024[63]. - Cash and cash equivalents at the end of the period rose to $3,682,000, compared to $2,868,000 at the end of the first half of 2024, marking an increase of approximately 28.4%[23]. - The Group had cash and bank balances of $3.7 million as of March 31, 2025, up from $3.5 million as of September 30, 2024[87]. Shareholder Information - The Board has resolved not to declare the payment of dividend for the Relevant Period[18]. - The Group has not declared any dividends for 2025H1, consistent with 2024H1[49]. - Mr. Chua Liang Sie holds a long position of 552,000,000 shares, representing 69% of the total issued shares[116]. - Mr. Chua Liang Chui also holds a long position of 552,000,000 shares, representing 69% of the total issued shares[116]. - YJH Group Limited is approximately 82.76% owned by Mr. Chua Liang Sie and 17.24% by Mr. Chua Liang Chui[117]. - The company’s retained earnings increased to $4,318,000 as of March 31, 2025, compared to $3,916,000, reflecting a growth of approximately 10.3%[22]. Corporate Governance and Compliance - The unaudited financial statements are prepared in accordance with International Accounting Standard 34, ensuring compliance with applicable regulations[29]. - The Company has adopted the Required Standard of Dealings, and all Directors confirmed compliance during the Relevant Period[129]. - The Audit Committee consists of three independent non-executive Directors, who have reviewed the unaudited condensed consolidated financial statements for the Relevant Period[140]. - The Company has adopted and complied with the Corporate Governance Code, with a noted deviation regarding the roles of Chairman and Chief Executive Officer being held by the same individual[139]. - The company maintains compliance with the GEM Listing Rules regarding the disclosure of interests and positions[120]. Future Outlook and Strategy - The company is optimistic about industry growth in Singapore, emphasizing the necessity of tissue products[67][68]. - The company aims to achieve sustainable growth and greater returns for shareholders through continuous evaluation of development opportunities[68]. - Future outlook indicates a projected revenue growth of 15% for FY2025 compared to FY2024[149]. - The company plans to invest in new technology for tissue production, aiming to increase efficiency by 20%[150]. - The company is exploring potential acquisitions to strengthen its supply chain and distribution network[150]. - New product lines are expected to launch in Q3 2024, targeting both domestic and international markets[149]. - Ongoing research and development efforts are focused on sustainable materials, with a target of 30% recycled content in products by 2025[149]. - The company aims to enhance shareholder value through strategic initiatives and operational improvements[150].

CHARACTERISTICS OF GEM GEM之特色 Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this report, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this report. 本報告的資料乃遵照GEM上市規則而刊載，旨在 提供有關本公司的資料；董事願就本報告的資料 共同及個別地承擔全部責任。董事在作出一切合 理查詢後確認，就其所深知及確信，本報告所載 資料在各重要方面均屬準確完備，並無誤導或欺 詐成分，且並無遺漏任何其他事項，足以令致本 報告或其所載任何陳述產生誤 ...

Financial Performance - Sunlight Holdings reported a consolidated revenue of SGD 10 million for the fiscal year ending September 30, 2024, representing a 15% increase compared to the previous year[2]. - The company achieved a net profit of SGD 2 million, which is a 20% increase year-over-year, indicating improved operational efficiency[2]. - Revenue decreased by 3.7% from $14.6 million in the Previous Year to $14.1 million in the Relevant Year[23]. - Gross profit increased by 6.0% from $4.5 million in the Previous Year to $4.8 million in the Relevant Year[23]. - Profit increased by 13.1% from $650,000 in the Previous Year to $735,000 in the Relevant Year[23]. - Revenue for the Relevant Year was $14.1 million, a decrease of $0.5 million or 3.7% compared to the Previous Year revenue of $14.6 million[49]. - Cost of sales decreased from $10.1 million to $9.3 million, representing a decrease of 8.0%[56]. - Gross profit increased from $4.5 million to $4.8 million, with a gross profit margin increase from 31.1% to 34.2%, representing an increase of 310 basis points[57]. - Selling and distribution expenses increased from $1.7 million to $1.9 million, representing an increase of 8.1%[58]. - Profit attributable to the owners of the Company was $735,000 in the Relevant Year, an increase from $650,000 in the Previous Year[59]. - Total assets at the end of the Relevant Year were $21.8 million, up from $20.3 million in the Previous Year[64]. - Cash and cash equivalents at the end of the Relevant Year were $3.5 million, an increase from $1.7 million in the Previous Year[64]. - Total staff costs in the Relevant Year amounted to $2.8 million, an increase of 12% from the previous year's $2.5 million[72]. Market Expansion and Strategy - User data showed a growth in active customers by 25%, reaching a total of 50,000 users as of September 30, 2024[2]. - Sunlight Holdings plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share over the next two years[2]. - Future guidance indicates expected revenue growth of 10-15% for the next fiscal year, driven by new product launches and market expansion[2]. - The company has initiated a strategic partnership with a local distributor to enhance its supply chain efficiency, aiming for a 5% reduction in logistics costs[2]. - Sunlight Holdings is exploring potential acquisition opportunities to diversify its product offerings and strengthen its market position[2]. - The company continues to evaluate development opportunities to maintain its market-leading position[25]. Sustainability and Environmental Goals - Sunlight Holdings is committed to sustainability, with plans to reduce carbon emissions by 20% over the next three years through various initiatives[2]. - The company integrates environmental and social considerations into its business objectives to achieve specific environmental and social goals[109]. - Environmental goals include reducing greenhouse gas emissions and improving waste management practices[109]. - The company acknowledges its responsibility to protect the environment and has integrated environmental considerations into its operations[116]. - The company has implemented energy-saving measures, including setting air-conditioning at environmentally friendly levels and using motion-sensor lighting[120]. - The company has set emission reduction targets and is actively implementing steps to achieve them[164]. - The total energy consumption reported is categorized by type, with specific metrics on direct and indirect usage[167]. - The company has established energy efficiency targets and is taking measures to meet these goals[167]. Employee and Workplace Practices - The Group had an aggregate of 36 employees at the end of the Relevant Year, a decrease from 37 employees in the previous year[71]. - The employee turnover rate during the Relevant Year was 18%, up from 7% in the previous year[147]. - The company provides competitive remuneration packages to attract qualified applicants based on market conditions[136]. - The company has a staff handbook to inform employees of goals, policies, and responsibilities, which is updated as necessary[137]. - The company is committed to creating a workplace based on respect for human rights, allowing employees to practice their beliefs freely[141]. - The company reported no work-related fatalities or serious injuries during the Relevant Year, with no days lost due to stop-work orders issued by the Ministry of Manpower (MOM)[150]. - The company's comprehensive workplace safety health system is certified to BizSAFE Level 3 by the Workplace Safety and Health Council of Singapore[150]. - The company encourages employees to develop their skills, although no requests for training were received during the Relevant Year[150]. - Training activities are conducted to improve employees' skills, with metrics on the percentage of employees trained[186]. - The average training hours completed per employee are monitored, categorized by gender and employee category[186]. Corporate Governance and Compliance - The company recognizes its corporate social responsibility and oversees ESG issues through its Board[105]. - The governance aspect of the ESG Guide is addressed in the Corporate Governance Report of the annual report[103]. - The company prohibits employees from receiving advantages from customers, suppliers, or other parties while performing their duties, with no reports of non-compliance incidents related to corruption during the Relevant Year[153]. - The company provides annual publications on anti-corruption practices to directors and senior management, particularly before the Lunar New Year[153]. - Policies are in place for managing environmental and social risks in the supply chain[200]. Supply Chain Management - Major suppliers during the Relevant Year included two from ASEAN and one from China, indicating a focus on regional supply chain management[153]. - The company regularly evaluates supplier performance based on capacity, delivery accuracy, and environmental protection[153]. - The company emphasizes environmental compliance by requiring suppliers to provide FSC-certified products[153]. - Practices to promote environmentally preferable products and services when selecting suppliers are implemented and monitored[200].

Financial Performance - The Group's revenue for the Relevant Period was $7.1 million, a slight decrease of $0.1 million or 1.7% compared to $7.2 million in the Previous Period[12]. - The Group's profit for the Relevant Period was $506,000, an increase from a profit of $244,000 in the Previous Period[12]. - Gross profit for 2024H1 was $2.494 million, compared to $1.967 million in 2023H1, reflecting an increase in gross profit margin[14]. - The total comprehensive income for the period increased to $506,000 for 2024H1, up from $244,000 in 2023H1, representing a growth of 106.15%[17]. - Consolidated profit before taxation for H1 2024 was $596,000, up from $244,000 in H1 2023[42]. - Basic earnings per share for H1 2024 was 0.06 cents, compared to 0.03 cents in H1 2023, reflecting a 100% increase[52]. - The profit attributable to shareholders for the period was $506,000, compared to $244,000 in the same period last year, representing a significant increase[92]. Assets and Liabilities - Current assets as of March 31, 2024, totaled $5.973 million, compared to $5.687 million as of September 30, 2023[16]. - Total assets as of March 31, 2024, were $20.256 million, slightly down from $20.317 million as of September 30, 2023[16]. - Total equity attributable to shareholders increased to $17.334 million from $16.828 million[16]. - Trade and other receivables decreased to $2.130 million from $2.951 million[16]. - The Group's cash and cash equivalents increased to $2.868 million from $1.722 million[16]. - Total liabilities decreased to $2.9 million from $3.5 million as of September 30, 2023[95]. - The current ratio improved to 5.4 times as of March 31, 2024, up from 3.5 times as of September 30, 2023, indicating better liquidity[95]. Expenses - Selling and distribution expenses rose to $914,000 from $876,000, indicating increased operational costs[14]. - Administrative expenses increased from $0.9 million to $1.0 million, representing an increase of 19.6% due to global inflation[84][90]. - Cost of sales decreased from $5.2 million to $4.6 million, representing a decrease of 12.4% due to lower purchase costs following the normalization of sea freight rates post COVID-19[82][88]. - The cost of inventories for H1 2024 was $4,152,000, down from $4,831,000 in H1 2023[44]. Dividends - The Board has resolved not to declare any dividend for the Relevant Period[12]. - The Board has resolved not to declare any dividend for H1 2024, consistent with H1 2023[49]. - The board has approved a dividend payout of MYR 0.05 per share, reflecting a commitment to returning value to shareholders[172]. Operational Insights - The principal activity of the group remains focused on supplying tissue products to corporate customers in Singapore, with no new segments reported[31]. - The Group's operations are solely based in Singapore, with all non-current assets located there[42]. - The company is optimistic about industry growth in Singapore, as tissue products are daily necessities[74]. - The company plans to continue evaluating development opportunities to strengthen its competitive advantage and market position[75]. Strategic Initiatives - The company is investing HK$50 million in R&D for new technologies aimed at enhancing product efficiency[168]. - Market expansion plans include entering two new Southeast Asian countries by the end of 2024[169]. - The company is considering strategic acquisitions to enhance its market position, with a budget of up to HK$100 million allocated for potential deals[170]. - A new marketing strategy is being implemented to increase brand awareness, targeting a 15% increase in customer engagement by the end of 2024[166]. Shareholder Information - As of the end of the Relevant Period, Mr. Chua Liang Sie holds a long position of 552,000,000 shares, representing 69% of the total issued shares[130]. - Mr. Chua Liang Chui also holds a long position of 552,000,000 shares, representing 69% of the total issued shares[130]. - YJH Group Limited, an associated corporation, is owned approximately 82.76% by Mr. Chua Liang Sie and 17.24% by Mr. Chua Liang Chui[132]. Governance and Compliance - The company has adopted the Required Standard of Dealings, and all Directors confirmed compliance during the Relevant Period[144]. - The company has entered into a Deed of Non-competition with its Controlling Shareholders to prevent any competition with its businesses[145]. - The Audit Committee consists of three independent non-executive Directors, who have reviewed the unaudited condensed consolidated financial statements for the Relevant Period[156]. - The company has adopted and complied with the Corporate Governance Code, with a noted deviation regarding the roles of Chairman and Chief Executive Officer being held by the same individual[155]. Future Outlook - The company provided a positive outlook for FY2024, projecting a revenue growth of 10% to 12%[166]. - New product launches are expected to contribute an additional 5% to revenue in the second half of 2024[167]. - The company reported a significant increase in revenue for the first half of 2024, achieving MYR 150 million, representing a 20% growth compared to the previous period[172]. - User data showed a rise in active users to 1.2 million, up 15% from the previous half-year[172]. - The company provided an optimistic outlook for the second half of 2024, projecting a revenue increase of 25% year-on-year[172].

Financial Performance - The Group's revenue for the Relevant Period was $7.1 million, representing a slight decrease of $0.1 million or 1.7% compared to $7.2 million in the Previous Period[20] - The Group's profit for the Relevant Period was $506,000, an increase from a profit of $244,000 in the Previous Period[20] - Gross profit for the first half of 2024 was $2.494 million, compared to $1.967 million in the first half of 2023[22] - Profit before taxation for the first half of 2024 was $596,000, compared to $244,000 in the first half of 2023[22] - Profit for the period increased to $506,000 for the first half of 2024, compared to $244,000 for the same period in 2023, marking a 107.4% increase[25] - The Group's consolidated profit before taxation for 2024H1 was $596,000, compared to $244,000 in 2023H1, representing a significant increase of 144.3%[50] - Basic earnings per share for 2024H1 was 0.06 cents, doubling from 0.03 cents in 2023H1[62] - The Group did not declare any dividends for 2024H1, consistent with 2023H1[57] Expenses and Costs - Selling and distribution expenses increased to $914,000 from $876,000 year-on-year[22] - Administrative expenses rose to $1.021 million from $854,000 year-on-year[22] - Cost of sales decreased to $4.573 million from $5.222 million year-on-year[22] - Cost of sales decreased from $5.2 million to $4.6 million, representing a decrease of 12.4% due to lower purchase costs from the normalization of sea freight rates post COVID-19[92] - Total unallocated expenses for 2024H1 were $1,935,000, compared to $1,730,000 in 2023H1, indicating an increase of 11.8%[50] Assets and Liabilities - Total assets as of March 31, 2024, amounted to $20,256,000, a slight decrease from $20,317,000 as of September 30, 2023[24] - Current liabilities decreased to $1,097,000 from $1,634,000, a reduction of approximately 32.8%[24] - Trade and other receivables decreased to $2,130,000 from $2,951,000, a decline of about 27.8%[24] - Non-current liabilities remained stable at $1,825,000, slightly down from $1,855,000[24] - The Group's total assets remained stable at $20.3 million as of March 31, 2024, with total liabilities decreasing to $2.9 million from $3.5 million[105] Cash Flow and Liquidity - Cash and cash equivalents increased to $2,868,000 from $1,722,000, representing a 66.6% increase[27] - Net cash generated from operating activities for the first half of 2024 was $1,173,000, compared to $436,000 in the same period of 2023, indicating a significant improvement[27] - The company reported a net increase in cash and bank balances of $1,146,000 for the first half of 2024, compared to an increase of $265,000 in the first half of 2023[27] - Cash and bank balances increased to $2.9 million from $1.8 million, indicating improved liquidity[106] Shareholder Equity - Total equity attributable to shareholders rose to $17,334,000, up from $16,828,000, reflecting a 3% increase[25] - The company’s retained earnings increased to $3,916,000 as of March 31, 2024, up from $3,410,000, reflecting a growth of 14.8%[25] - Retained earnings increased from $3,410,000 as of September 30, 2023, to $3,916,000 as of March 31, 2024[69] Corporate Governance - The company’s corporate governance practices are in compliance with the GEM Listing Rules[138] - The Company has adopted and complied with the Corporate Governance Code, with a noted deviation regarding the roles of Chairman and Chief Executive Officer being held by the same individual[165] - The Audit Committee consists of three independent non-executive Directors, who reviewed the unaudited condensed consolidated financial statements for the Relevant Period[166] - The board of Directors includes both executive and independent non-executive Directors, ensuring a balance of powers[171] Future Outlook and Strategy - The company is optimistic about industry growth in Singapore, as tissue products are daily necessities[84] - The company plans to continue evaluating development opportunities to strengthen its competitive advantage and market position[85] - The company provided a future outlook, projecting a revenue growth of 10-12% for the full year 2024[182] - New product launches are expected to contribute an additional MYR 15 million in revenue by Q3 2024[182] - The company is expanding its market presence in Southeast Asia, targeting a 25% increase in market share by the end of 2024[182] - The company is considering strategic acquisitions to enhance its product portfolio, with potential targets identified in the region[182] Operational Developments - The company completed the upgrade of its conversion line for the production of jumbo roll tissues, achieving commercial production as planned[135] - The manufacturer was in the process of upgrading the machine for the production of hand towels, with no commercial production achieved during the relevant period[135] - The extension of the existing factory building and the purchase of lifting equipment were both completed as scheduled[135] - The company’s operational activities during the relevant period were primarily focused on upgrading existing production capabilities rather than expanding new product lines[135] Risks and Compliance - Forward-looking statements in the report involve known and unknown risks that could cause actual results to differ materially from expectations[170] - The company anticipates future events and performance may differ significantly due to known and unknown risks[172]

Financial Performance - Revenue increased by 21.4% from SGD 12.0 million in the Previous Year to SGD 14.6 million in the Relevant Year as COVID-19 restrictions were fully lifted[20] - Gross profit increased by 63.0% from SGD 2.8 million in the Previous Year to SGD 4.5 million in the Relevant Year due to constant adjustments in selling prices[20] - Profit increased by 150.0% from SGD 260,000 in the Previous Year to SGD 650,000 in the Relevant Year[20] - Revenue for the Relevant Year was $14.6 million, representing an increase of $2.6 million or 21.4% compared to the Previous Year revenue of $12.0 million[37] - Revenue from external customers for tissue products was $13.0 million, with segment profit of $3.9 million[52] - Annual revenue increased to $14.6 million, up $2.6 million or 21.4% from the previous year[54] - Sales of tissue products rose by $2.4 million, representing a 23.0% increase due to normal commercial activities without COVID-19 restrictions[55] - Gross profit increased from $2.8 million to $4.5 million, with gross profit margin rising from 23.1% to 31.1%, an increase of 800 basis points[57] - Profit attributable to owners increased to $650,000 from $260,000 in the previous year[61] - Total assets at the end of the year were $20.3 million, financed by total liabilities of $3.5 million and shareholders' equity of $16.8 million[69] Operational Developments - The company upgraded its conversion line for the production of jumbo roll tissues during the Relevant Year[19] - The conversion line for the production of jumbo roll tissues has been upgraded, and commercial production has commenced[96][100] - The extension of the existing factory building has been completed, and lifting equipment has been purchased[100][101] - The company has unutilized banking facilities of $3.5 million on standby to support operations[51] - The company continues to monitor operating costs and administration expenses closely[51] Market Conditions - The absence of COVID-19 restrictions in the Relevant Year led to a normal level of commercial activities, resulting in increased customer orders for tissue products[18] - There were no COVID-19 restrictions imposed during the Relevant Year, leading to normal commercial activities and increased orders for tissue products[35] Employee and Governance - All employees are vaccinated against COVID-19, and the company adheres strictly to government directives on COVID-19 precautions[51] - The management team has extensive experience, with key executives averaging over 30 years in their respective fields, ensuring strong leadership[128][130] - Financial oversight is managed by a seasoned CFO with 35 years of experience in audit and corporate finance, ensuring sound financial management[128] Sustainability and ESG Initiatives - The company is committed to sustainability, with ongoing efforts to improve environmental practices in production processes[138] - The company integrates environmental and social considerations into its business objectives to achieve specific environmental and social goals[166] - Environmental goals include adding environmentally friendly elements in daily operations, using energy and resources efficiently, reducing greenhouse gas emissions, and improving waste management[166] - Social goals focus on respecting employees' rights, promoting an equal opportunity workplace, ensuring occupational safety and health, and supporting community participation[166] - A dedicated team has been established to develop and monitor environmental and social policies, ensuring proper assessment and management of ESG matters[168] - The company maintains open communication with stakeholders to understand the impact of business decisions on them[169] - Key Performance Indicators (KPIs) are disclosed to measure actual results and ensure effective ESG risk management[172] - The Board oversees ESG issues and evaluates material risks posed to the Group, neutralizing identified risks[150] - The company commits to ethical business practices and building integrity within the workplace[166] - Regular updates on KPI targets and progress towards environmental and social goals are provided to the Board[154] - The company aims for sustainability of ESG aspects as a core commitment to long-term value creation for stakeholders[159] Environmental Impact - The company does not produce hazardous waste as part of its operations[189] - The company has implemented green office measures, adopting the 3R concept of "reduce, reuse and recycle" to enhance environmental awareness among employees[195] - The company monitors electricity consumption in kWh instead of GHG emissions, as it has no control over the source of electricity generation in Singapore[187] - The company does not set efficiency targets for water consumption, which is minimal and supplied by the government[197] - Water consumption data is unavailable due to a malfunctioning water meter, with the previous year's consumption recorded at 1,021 m³[200] - Electricity consumption increased to 118,000 kWh from 65,000 kWh in the previous year, representing an increase of approximately 81.54%[200] - Diesel consumption decreased to 33,405 liters from 34,482 liters, showing a reduction of about 3.13%[200] - Diesel consumption per 1,000 delivery orders improved to 1,776 liters from 1,916 liters, a decrease of approximately 7.29%[200] - Diesel consumption per 1,000 units delivered improved to 61 liters from 74 liters, a decrease of about 17.57%[200] - The company has achieved its environmental goals for the relevant year[199] - The company engages with stakeholders to identify material ESG issues, with no significant issues arising during the Relevant Year[176]

香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公告之內 容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不對因本公 告全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 SUNLIGHT (1977) HOLDINGS LIMITED 日 光（1977）控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：8451） 截至2023年9月30日止年度之 年度業績公告 日光(1977)控股有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈本公司及其 附屬公司截至2023年9月30日止年度之經審核綜合業績。 本公告載列本公司2023年年報（「年報」）全文，並符合聯交所GEM證券上市規則 （「GEM上市規則」）內有關年度業績初步公告須附載資料的相關規定。年報之印刷 版本載有GEM上市規則所規定之資料，將按照GEM上市規則所規定之方式適時寄 發予本公司股東。 代表 日光(1977)控股有限公司 主席兼行政總裁 蔡良聲 新加坡，2023年12月15日 ...

Financial Performance - Revenue for Q3 2023 increased to SGD 10,794,000, up 27.1% from SGD 8,488,000 in Q3 2022[12] - Gross profit for Q3 2023 was SGD 3,026,000, representing a 53.9% increase compared to SGD 1,966,000 in Q3 2022[12] - Profit before taxation for Q3 2023 was SGD 461,000, a significant turnaround from a loss of SGD 30,000 in Q3 2022[12] - Earnings per share for Q3 2023 rose to 0.06 cents, compared to 0.01 cents in Q3 2022[12] - Total comprehensive income for the period in Q3 2023 was SGD 461,000, compared to SGD 70,000 in Q3 2022[12] - Profit attributable to equity holders for Q3 2023 was $461,000, reflecting a significant increase of 558.6% from $70,000 in Q3 2022[33] - Revenue for Q3 2023 was $10.8 million, an increase of 27.2% compared to Q3 2022, driven by higher orders of tissue products from corporate customers[39] - Tissue products revenue reached $9.63 million in Q3 2023, up from $7.46 million in Q3 2022, marking a growth of 29.1%[28] - Hygiene-related products generated revenue of $664,000 in Q3 2023, compared to $619,000 in Q3 2022, an increase of 7.3%[28] Expenses and Cost Management - Selling and distribution expenses increased to SGD 1,306,000 in Q3 2023 from SGD 1,081,000 in Q3 2022[12] - Administrative expenses rose to SGD 1,302,000 in Q3 2023, up from SGD 1,010,000 in Q3 2022[12] - Cost of sales increased from $6.5 million to $7.8 million, representing a 19.1% increase[56] - Selling and distribution expenses rose from $1.1 million to $1.3 million, an increase of 20.8%[57] - Administrative expenses increased from $1.0 million to $1.3 million, reflecting a 28.9% rise due to global inflation[58] - The cost of inventories for Q3 2023 was $7.12 million, up from $6.03 million in Q3 2022, representing an increase of 18.1%[29] Market Presence and Strategy - The company continues to focus on expanding its market presence in Singapore, primarily in the tissue products sector[18] - The Group is engaged in supplying tissue products to corporate customers, indicating a stable business model[18] - The company is optimistic about achieving sustainable growth and is committed to delivering greater returns to shareholders[51] - The company plans to expand its market reach into Southeast Asia, targeting a market share increase of FF% by the end of FY2024[109] - Market expansion efforts have led to a 30% increase in sales in the Southeast Asia region[114] Corporate Governance and Compliance - The company has adopted the Corporate Governance Code, with a noted deviation regarding the roles of Chairman and CEO being held by the same individual[95] - The Audit Committee consists of three independent non-executive Directors, ensuring proper oversight of financial statements[96] - All Directors confirmed compliance with the Required Standard of Dealings during the Relevant Period[85] - There are no known conflicts of interest involving directors or controlling shareholders during the relevant period[93] - The company has established a non-competition agreement with its controlling shareholders to prevent direct or indirect competition[92] Future Outlook and Growth Initiatives - The company anticipates a revenue growth of BB% for the upcoming quarter, driven by new product launches and market expansion strategies[109] - Research and development efforts have led to the introduction of two new products, expected to contribute an additional HK$CC million in revenue[111] - The company is exploring potential acquisitions to enhance its market presence and diversify its product offerings[109] - A new strategic partnership was announced, expected to enhance distribution channels and increase sales by 15%[114] - The company is investing $2 million in R&D for new technologies aimed at enhancing product efficiency[116] Shareholder Information - Mr. Chua Liang Sie holds 576,000,000 shares, representing 72% of the total issued shares of the company[69] - Mr. Chua Liang Chui also holds 576,000,000 shares, representing 72% of the total issued shares of the company[69] - YJH Group Limited is approximately 82.76% owned by Mr. Chua Liang Sie and 17.24% by Mr. Chua Liang Chui[73] - The company has not declared any dividends for Q3 2023, consistent with Q3 2022[33] Operational Efficiency - The financial results reflect a positive trend in operational efficiency and profitability for the Group[12] - The company continues to generate positive operating cash flow and has sufficient funds to meet working capital needs[47] - The Group maintained a net current asset position of $2.8 million as of September 30, 2022, ensuring sufficient funds for working capital requirements[40] - The Group's operations were not significantly impacted by COVID-19 during the Relevant Period, with delivery and receipt of products continuing as planned[38]

香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公告之內 容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不對因本公 告全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 SUNLIGHT (1977) HOLDINGS LIMITED 日 光（1977）控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：8451） 截至2023年6月30日止九個月的 第三季度業績公告 日光(1977)控股有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈，本公司及 其附屬公司截至2023年6月30日止九個月之未經審核簡明綜合業績。本公告載列 本公司2023第三季度報告（「報告」）全文，並符合聯交所GEM證券上市規則（「GEM 上市規則」）內有關第三季度業績初步公告附載資料的相關規定。報告之印刷版本 載有GEM上市規則所規定之資料，將按照GEM上市規則所規定之方式適時寄發予 本公司股東。 代表 日光(1977)控股有限公司 主席兼行政總裁 蔡良聲 新加坡，2023年8月10日 ...